Anti-AAV8 Antibodies and ELISA Kits Complete Resource for AAV8 Detection and Quantification

Adeno-associated virus serotype eight (AAV8) has emerged as one of the most powerful and widely utilized viral vectors for human gene therapy. Distinguished by its exceptional ability to transduce liver tissue with high efficiency following systemic administration, AAV8 has become the vector of choice for numerous hepatic gene therapy applications. Unlike many other AAV serotypes, AAV8 exhibits remarkable tropism for hepatocytes, achieving efficient transduction rates in animal models at moderate vector doses. This unique property has positioned AAV8 at the forefront of clinical development for hemophilia, familial hypercholesterolemia, Crigler-Najjar syndrome, and other inherited metabolic disorders affecting the liver.AAV8 exhibits minimal transduction of non-target tissues following intravenous administration, as the majority of vector particles are sequestered by the liver. This favorable biodistribution profile enhances both efficacy and safety by concentrating the therapeutic payload in the intended organ system. Additionally, AAV8 demonstrates excellent stability in the bloodstream, resisting neutralization and degradation longer than many other serotypes, which contributes to its effectiveness following systemic delivery. Despite its promise, the successful development and clinical translation of AAV8-based gene therapies depend critically on accurate monitoring of host immune responses against the vector. Preexisting neutralizing antibodies and treatment-emergent anti-AAV8 antibodies can significantly reduce transduction efficiency, limit therapeutic efficacy, and pose patient safety risks. Reliable serological detection of anti-AAV8 antibodies is therefore essential for patient screening, dose stratification, and post-treatment monitoring. This page provides a comprehensive overview of AAV8 biology, its applications in gene therapy, and validated detection solutions including human and mouse anti-AAV8 antibody ELISA kits.

Figure 1.Anti-AAV8 Antibodies and ELISA Kits.

Clinical Applications

Advantages of AAV8 Over Other Serotypes

AAV8 offers several distinct advantages for liver-directed gene therapy. First, its high efficiency allows for lower vector doses, reducing manufacturing costs and minimizing the risk of dose-related toxicities. Second, AAV8 demonstrates minimal transduction of non-target tissues, concentrating the therapeutic effect in the liver. Third, the prevalence of preexisting neutralizing antibodies against AAV8 in human populations is generally lower than for AAV2, a historically common serotype, making more patients eligible for treatment. Fourth, AAV8 vectors mediate sustained transgene expression with minimal decline over time in most animal models and clinical studies.

Mouse Anti-AAV8 Antibody ELISA Kit

The Mouse Anti-AAV8 Antibody ELISA Kit is specifically designed for preclinical gene therapy studies using murine models. This kit enables researchers to assess the immunogenicity of AAV8-based vectors in mice, a critical parameter for vector optimization and dose selection.

Key Features

• Species-Specific Detection: Uses secondary antibodies optimized for mouse IgG, eliminating cross-reactivity with other immunoglobulins or with the therapeutic vector itself.
• Sample Compatibility: Validated for mouse serum, plasma, and cell culture supernatants from all common laboratory mouse strains.
• Low Sample Volume Requirement: Requires a minimal volume of sample per well, conserving valuable material from small-volume mouse bleeds.
• High Reproducibility: Rigorously tested for intra- and inter-assay precision, meeting the requirements of GLP-compliant preclinical studies.
• Easy Data Interpretation: Includes a detailed protocol with representative standard curves and acceptance criteria for quality control.